Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)

Condition:   Non-small Cell Lung Cancer NSCLC Interventions:   Drug: Durvalumab;   Drug: Placebo for Olaparib;   Drug: Olaparib;   Drug: Nab-paclitaxel+carboplatin;   Drug: Gemcitabine+carboplatin;   Drug: Pemetrexed+carboplatin;   Drug: Gemcitabine+cisplatin;   Drug: Pemetrexed+cisplatin Sponsor:   AstraZeneca Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials